FDA panel backs Biosense Webster's catheter for atrial fibrillation

A US FDA advisory panel has unanimously recommended approval of an ablation catheter developed by Biosense Webster for the treatment of atrial fibrillation (AF). The FDA is not required to follow the panel's advice, though it usually does.

A US FDA advisory panel has unanimously recommended approval of an ablation catheter developed by Biosense Webster for the treatment of atrial fibrillation (AF). The FDA is not required to follow the panel's advice, though it usually does.

The agency's circulatory system devices panel backed the NaviStar ThermoCool catheter for the treatment of symptomatic paroxysmal AF. The device...

More from Archive

More from Medtech Insight